Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) a specialty pharmaceutical company, announced a poster presentation at the American Academy of Neurology (AAN) 66th Annual Meeting, April 26 to May 3, 2014, in Philadelphia, PA.Adamas Pharmaceuticals Inc (NASDAQ:ADMS) shares after opening at $15.39 moved to $15.96 on last trade day and at the end of the day closed at $15.69. Company price to sales ratio in past twelve months was calculated as 3.62 and price to cash ratio as 3.01. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) showed a positive weekly performance of 20.60%.
The Compensation Committee of the Board of Directors of Versartis, Inc (NASDAQ:VSAR) approved (a) one-time cash bonus payments and (b) grants of restricted stock units (the “RSUs”) for each of the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission). The RSUs were granted pursuant to the Company’s 2014 Equity Incentive Plan (the “Plan”).Versartis Inc (NASDAQ:VSAR) shares advanced 0.20% in last trading session and ended the day on $29.95. Versartis Inc (NASDAQ:VSAR) return on equity ratio is recorded as 142.80% and its return on assets is -515.40%.
Galectin Therapeutics Inc. (NASDAQ:GALT) the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced that all eight (8) patients have received their first infusion in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis. Patients in cohort 2 were successfully dosed with 4 mg/kg, which is double the dose given in cohort 1. The clinical trial protocol specifies that eight patients are included in cohort 2; however, an additional two patients may be enrolled to ensure the requisite number of eight patients complete the 63-day protocol in the second cohort.Galectin Therapeutics Inc. (NASDAQ:GALT) shares moved down -7.76% in last trading session and was closed at $11.06 while trading in range of $10.90 – $11.89 – Galectin Therapeutics Inc. (NASDAQ:GALT) year to date (YTD) performance is 36.88 %.
Fibrocell Science, Inc. (NYSEMKT:FCSC)’s Gregory Weaver, senior vice president and chief financial officer of Fibrocell Science, presented at the Alliance for Regenerative Medicine’s (ARM) 2nd Annual Regen Med Investor Day at 4:00 p.m. EDT on Wednesday, March 26, 2014 at the Metropolitan Club in New York, and the BioCentury Future Leaders in the Biotech Industry conference at 10:30 a.m. EDT on Friday, March 28, 2014 at the Millennium Broadway Hotel & Conference Center in New York. Fibrocell Science Inc (NYSEMKT:FCSC) weekly performance is -7.02%. On last trading day company shares ended up $3.84. Fibrocell Science Inc (NYSEMKT:FCSC) distance from 50-day simple moving average (SMA50) is -26.73%. Analysts mean target price for the company is $8.42.
Leave a Reply